Capital Cell

MediQuo is a health-focused application that facilitates communication between patients and healthcare professionals, effectively serving as a "hospital in your pocket." The app addresses the high volume of unnecessary medical visits by enabling remote consultations through chat, video, and audio communication. MediQuo is compliant with GDPR regulations, ensuring the privacy and security of patient information while allowing healthcare providers to manage their time efficiently. The platform supports the exchange of medical files, including images and reports, enhancing diagnostic capabilities. With features for scheduling appointments and immediate 24/7 medical responses, MediQuo has garnered significant traction, achieving over 1 million consultations and 600,000 downloads. It maintains a high user satisfaction rating of 4.6 on Google Play, positioning itself among the leading health apps in Spain and Latin America.

Oncostellae SL is a Spanish biotechnology company, founded in 2013 and headquartered in Ourense. Specializing in the development of small molecule drugs specifically for cancer treatment, Oncostellae is comprised of a team of researchers with expertise in chemistry, biochemistry, and pharmacology. The company focuses on creating pharmaceutical research programs aimed at discovering novel modulators of validated cancer targets, including nuclear receptors and kinases. Oncostellae employs a streamlined approach, managing internal activities such as project management, medicinal chemistry, and in vitro pharmacology while subcontracting other research and development processes, including in vivo studies, toxicology, and clinical trials, to qualified external providers. The company's commercial strategy involves licensing clinical drug candidates, along with their associated intellectual property and preclinical and clinical data, to established pharmaceutical or biotechnology firms.

Mowoot is a company that specializes in developing wearable medical devices aimed at improving the quality of life for individuals suffering from chronic constipation. Founded in 2014 and based in Barcelona, Spain, Mowoot offers a non-pharmacological and non-invasive solution that simulates a manual abdominal massage performed by healthcare professionals. Utilizing advanced pneumatic technology, its device provides automatic colon-specific massages to stimulate intestinal transit, thereby helping to treat and prevent chronic slow transit constipation without the need for colon cleansing supplements, enemas, or laxatives. Mowoot emerged from the MOEBIO dHEALTH program, drawing inspiration from concepts in design and business innovation.

Corify Care SL is a medical technology company based in Madrid, Spain, focused on advancing the treatment of cardiac arrhythmias, particularly atrial fibrillation. Founded in 2019, the company has developed ACORYS, a non-invasive electrocardiographic imaging device that allows healthcare professionals to visualize the electrical activity of the heart without the need for invasive catheters or complex imaging techniques like MRI or CT scans. This innovative device addresses the limitations of existing solutions by providing real-time mapping of cardiac arrhythmias, which can significantly enhance the clinical management of atrial fibrillation. Corify Care's technology aims to improve treatment outcomes for millions of patients in Europe, enabling effective diagnosis and personalized care during routine cardiology visits.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases. The company's technology centers on tissue regeneration by replicating the biomechanical environment of the aorta, creating an optimal setting for cell migration and proliferation within a bioresorbable platform. This approach aims to closely mimic the natural dynamics of the aorta, thereby enhancing the efficiency of vascular disease treatment.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases. The company's technology centers on tissue regeneration by replicating the biomechanical environment of the aorta, creating an optimal setting for cell migration and proliferation within a bioresorbable platform. This approach aims to closely mimic the natural dynamics of the aorta, thereby enhancing the efficiency of vascular disease treatment.

Ekuore is a technology company based in Valencia, Spain, founded in 2012, that specializes in the design, development, and marketing of medical devices that integrate health services with mobile technologies. The company focuses on creating mHealth devices aimed at revolutionizing sanitary teleassistance, allowing for efficient and cost-effective monitoring and control of patients. Ekuore's flagship product is a digital electronic stethoscope designed to track and monitor patients' conditions, particularly in diagnosing cardiovascular diseases. This device compares physiological parameters against a comprehensive database to provide objective diagnoses, enabling hospitals to conduct secure digital consultations and enhance patient care.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases. The company's technology centers on tissue regeneration by replicating the biomechanical environment of the aorta, creating an optimal setting for cell migration and proliferation within a bioresorbable platform. This approach aims to closely mimic the natural dynamics of the aorta, thereby enhancing the efficiency of vascular disease treatment.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Vytrus Biotech SL is a biotechnology company based in Barcelona, Spain, that specializes in the development, production, and commercialization of active ingredients derived from plant stem cells. Founded in 2009 as a spin-off from the University of Barcelona, the company leverages over 30 years of research in plant biotechnology to create high-value natural active ingredients primarily for the cosmetics and pharmaceutical industries. Its product offerings include a range of cosmetic solutions such as cell factor-rich plasma and phyto-peptidic fractions, as well as dermatologic and customized products. In 2016, the company changed its name from Phyture Biotech SL to Vytrus Biotech SL, reflecting its focus on innovative, plant-based active ingredients.

Bioprognos is a spin-off from the Hospital Clínic of Barcelona, focused on advancing clinical outcomes and enhancing the quality of life for cancer patients. The company specializes in developing innovative, non-invasive diagnostic solutions that are both accurate and cost-effective. Utilizing Multiple Biomarkers Disease Activity Algorithms (MBDAAs), Bioprognos provides early detection services and effective management of cancer by qualitatively identifying various neoplasia-associated biomarkers in body fluids. This technology empowers both patients and healthcare providers by delivering vital information through simple blood tests, aiding in the assessment of cancer as well as other health conditions and risks.

Capital Cell is a European equity crowdfunding platform based in Barcelona, Spain, that specializes in biotechnology and life sciences projects. Founded in 2014, the company serves as a meeting point for entrepreneurs and private investors, including venture capitalists and business angels, to facilitate funding for innovative medical science initiatives. By leveraging the power of the crowd, Capital Cell enables researchers and companies in the biotech sector to access a diverse pool of investment, thereby fostering the growth and development of cutting-edge solutions in healthcare.